collection
MENU ▼
Read by QxMD icon Read
search

Tolvaptan, Kidney and Hyponatremia

shared collection
33 papers 25 to 100 followers
By Isabel Acosta-Ochoa Nephrology senior staff. Valladolid. Spain
https://read.qxmd.com/read/30868608/urea-in-cancer-patients-with-chronic-siad-induced-hyponatremia-old-drug-new-evidence
#1
Alice Nervo, Valentina D'Angelo, Daniela Rosso, Eleonora Castellana, Francesco Cattel, Emanuela Arvat, Emidio Grossi
BACKGROUND: Syndrome of inappropriate antidiuresis (SIAD) is the main cause of hyponatremia in cancer patients. International guidelines indicate urea as an interesting option for chronic SIAD. Nevertheless, strong data to support its use is lacking and its role in oncologic patients has not been described so far. MATERIAL AND METHODS: We retrospectively analysed 36 cancer patients affected by moderate or profound SIAD-induced chronic hyponatremia, who started oral urea (initial daily dose 15 g or 30 g) without fluid restriction between July 2013 and July 2018...
March 13, 2019: Clinical Endocrinology
https://read.qxmd.com/read/30800291/vasopressin-aquaporin-2-pathway-recent-advances-in-understanding-water-balance-disorders
#2
REVIEW
Marianna Ranieri, Annarita Di Mise, Grazia Tamma, Giovanna Valenti
The alteration of water balance and related disorders has emerged as being strictly linked to the state of activation of the vasopressin-aquaporin-2 (vasopressin-AQP2) pathway. The lack of responsiveness of the kidney to the vasopressin action impairs its ability to concentrate the urine, resulting in polyuria, polydipsia, and risk of severe dehydration for patients. Conversely, non-osmotic release of vasopressin is associated with an increase in water permeability in the renal collecting duct, producing water retention and increasing the circulatory blood volume...
2019: F1000Research
https://read.qxmd.com/read/30784603/diabetes-insipidus-and-syndrome-of-inappropriate-antidiuretic-hormone-in-critically-ill-patients
#3
REVIEW
Anatole Harrois, James R Anstey
Diabetes insipidus and the syndrome of inappropriate antidiuretic hormone secretion lie at opposite ends of the spectrum of disordered renal handling of water. Whereas renal retention of water insidiously causes hypotonic hyponatremia in syndrome of inappropriate antidiuretic hormone secretion, diabetes insipidus may lead to free water loss, hypernatremia, and volume depletion. Hypernatremia and hyponatremia are associated with worse outcomes and longer intensive care stays. Moreover, pathologies causing polyuria and hyponatremia in patients in intensive care may be multiple, making diagnosis challenging...
April 2019: Critical Care Clinics
https://read.qxmd.com/read/30638918/the-role-of-tolvaptan-administration-after-cardiac-surgery-a-meta-analysis
#4
Ioannis Bellos, Dimitrios C Iliopoulos, Despina N Perrea
OBJECTIVE: To evaluate the efficacy and safety of tolvaptan in fluid management after cardiac surgery compared with conventional diuretic treatment. DESIGN: Systematic review of the literature with meta-analyses. SETTING: The Medline, Scopus, Cochrane Central Register of Controlled Trials, Clinicaltrials.gov, and Google Scholar databases were searched from inception to July 30, 2018. PARTICIPANTS: The study comprised 759 patients undergoing cardiac surgery...
December 6, 2018: Journal of Cardiothoracic and Vascular Anesthesia
https://read.qxmd.com/read/30569597/the-efficacy-of-long-term-treatment-with-tolvaptan-to-prolong-the-time-until-dialysis-initiation-in-patients-with-chronic-kidney-disease-and-heart-failure
#5
Akihito Tanaka, Emiko Hiramatsu, Yu Watanabe, Chiharu Ito, Hibiki Shinjo, Yasuhiro Otsuka, Asami Takeda
BACKGROUND: The short-term effectiveness of Tolvaptan (TLV) against heart failure has been established. TLV is known to decrease the worsening of renal function more than loop diuretics. Long-term TLV administration decreases the rate of re-hospitalization in heart failure and prevents deterioration of kidney function. If repeated hospitalization for heart failure can be prevented in patients having concurrent chronic kidney disease (CKD), the period until dialysis initiation may be prolonged...
December 19, 2018: Therapeutic Apheresis and Dialysis
https://read.qxmd.com/read/30550035/-the-pathway-of-vasopressin-as-a-pharmacological-target-in-nephrology-a-narrative-review
#6
Michi Recupero, Pierluigi Fulignati, Alessandro Naticchia, Silvia D'Alonzo, Francesca D'Ascenzo, Stefano Costanzi
ADH is a hormone secreted by neurohypophysis that plays different roles based on the target organ. At the renal level, this peptide is capable of causing electrolyte-free water absorption, thus playing a key role in the hydro-electrolytic balance. There are pathologies and disorders that jeopardize this balance and, in this field, ADH receptor inhibitors such as Vaptans could play a key role. By inhibiting the activation pathway of vasopressin, they are potentially useful in euvolemic and hypervolemic hypotonic hyponatremia...
December 2018: Giornale Italiano di Nefrologia: Organo Ufficiale Della Società Italiana di Nefrologia
https://read.qxmd.com/read/28652798/combined-aquaretic-and-diuretic-therapy-in-acute-heart-failure
#7
Michael Goyfman, Paul Zamudio, Kristine Jang, Jennifer Chee, Catherine Miranda, Javed Butler, Nand K Wadhwa
INTRODUCTION: Acute heart failure (AHF) is a leading cause of hospitalization and readmission in the US. The present study evaluated maximum diuresis while minimizing electrolyte imbalances, hemodynamic instability, and kidney dysfunction, to achieve a euvolemic state safely in a shorter period of time. METHODS AND RESULTS: A protocol of combined therapy with furosemide, metolazone, and spironolactone, with or without tolvaptan and acetazolamide, was used in 17 hospitalized patients with AHF...
2017: International Journal of Nephrology and Renovascular Disease
https://read.qxmd.com/read/25997504/safety-of-add-on-tolvaptan-in-patients-with-furosemide-resistant-congestive-heart-failure-complicated-by-advanced-chronic-kidney-disease-a-sub-analysis-of-a-pharmacokinetics-pharmacodynamics-study
#8
Naoto Tominaga, Keisuke Kida, Naoki Matsumoto, Yoshihiro J Akashi, Fumihiko Miyake, Kenjiro Kimura, Yugo Shibagaki
BACKGROUND: Treatment of congestive heart failure (CHF) with loop diuretics, such as furosemide, may be associated with complications, including worsening renal function and metabolic or electrolyte disturbances. Coadministration of tolvaptan, a selective vasopressin V2 receptor antagonist, can ameliorate such adverse events by reducing the required dose of loop diuretics; however, the safety of tolvaptan in patients with reduced renal function is not known. As a result, we conducted an exploratory clinical trial of tolvaptan in 22 patients with CHF and advanced chronic kidney disease (CKD)...
July 2015: Clinical Nephrology
https://read.qxmd.com/read/30454744/syndrome-of-inappropriate-antidiuresis
#9
REVIEW
Michael L Moritz
The syndrome of inappropriate antidiuresis (SIAD) is a common cause of hyponatremia in hospitalized children. SIAD refers to euvolemic hyponatremia due to nonphysiologic stimuli for arginine vasopressin production in the absence of renal or endocrine dysfunction. SIAD can be broadly classified as a result of tumors, pulmonary or central nervous system disorders, medications, or other causes such as infection, inflammation, and the postoperative state. The presence of hypouricemia with an elevated fractional excretion of urate can aid in the diagnosis...
February 2019: Pediatric Clinics of North America
https://read.qxmd.com/read/30449775/tolvaptan-efficiently-reduces-intracellular-fluid-working-toward-a-potential-treatment-option-for-cellular-edema
#10
Hiroaki Kawabata, Hirotsugu Iwatani, Yuko Yamamichi, Keiko Shirahase, Naoko Nagai, Yoshitaka Isaka
Objective Tolvaptan is a class of diuretics that reduce body water through aquaresis. One of the most prominent characteristics of these agents is that worsening of the renal function is less likely to occur. We investigated the underlying mechanism concerning the change in the intracellular fluid (ICF) when the body fluid is reduced. Methods In this retrospective observational study, five overhydrated CKD patients with edema or pleural effusion treated with tolvaptan were assessed by the bioelectrical impedance method twice: once before and once after tolvaptan therapy...
November 19, 2018: Internal Medicine
https://read.qxmd.com/read/30369583/effects-of-tolvaptan-on-volume-overload-in-patients-with-heart-failure
#11
Koichiro Kinugawa, Naoki Sato, Takayuki Inomata
The present meta-analysis aimed to evaluate effects of tolvaptan on fluid retention in patients with heart failure who were non-responsive to conventional treatment and to assess differences between effects of low (≤ 15 mg/day) and high (> 15 mg/day) tolvaptan doses.Randomized controlled trials comparing add-on tolvaptan therapy and placebo or therapy with other diuretics in patients with heart failure were identified through a database search. The primary outcomes were changes in body weight and urine volume, and the secondary outcomes were changes in serum sodium and creatinine levels...
October 25, 2018: International Heart Journal
https://read.qxmd.com/read/30147354/effects-of-tolvaptan-on-renal-function-in-chronic-kidney-disease-patients-with-volume-overload
#12
Shunji Suzuki, Norio Hanafusa, Kenji Kubota, Ken Tsuchiya, Kosaku Nitta
Background: Fluid overload in chronic kidney disease (CKD) is generally controlled by diuretics, with potentially harmful effects on renal function. The efficacy of tolvaptan, a vasopressin V2-receptor antagonist and aquaretic, has not been evaluated for fluid control in CKD with reduced renal function. Methods: Each patient from a group of 24 CKD patients on tolvaptan 15 mg/d plus conventional diuretics (T group) was matched by age and sex with a patient from a group of 24 CKD patients on conventional nonaquaretic diuretics alone not associated to tolvaptan other than tolvaptan (C group)...
2018: International Journal of Nephrology and Renovascular Disease
https://read.qxmd.com/read/30045645/economic-impact-of-tolvaptan-treatment-vs-fluid-restriction-based-on-real-world-data-among-hospitalized-patients-with-heart-failure-and-hyponatremia
#13
COMPARATIVE STUDY
Joseph F Dasta, Shirin Sundar, Sandra Chase, Melissa Lingohr-Smith, Jay Lin
OBJECTIVES: To estimate the cost difference associated with tolvaptan treatment vs. fluid restriction (FR) among hospitalized patients with heart failure (HF) and hyponatremia (HN) based on a real-world registry of HN patients. METHODS: An Excel-based economic model was developed to evaluate the cost impact of tolvaptan treatment vs. FR. Model input for hospital length of stay (LOS) was based on published data from the Hyponatremia Registry (HNR). Based on HNR data, tolvaptan-treated patients had a 2-day (median) shorter LOS compared to FR...
October 2018: Hospital Practice (Minneapolis)
https://read.qxmd.com/read/30026287/long-term-administration-of-tolvaptan-in-autosomal-dominant-polycystic-kidney-disease
#14
Marie E Edwards, Fouad T Chebib, Maria V Irazabal, Troy G Ofstie, Lisa A Bungum, Andrew J Metzger, Sarah R Senum, Marie C Hogan, Ziad M El-Zoghby, Timothy L Kline, Peter C Harris, Frank S Czerwiec, Vicente E Torres
BACKGROUND AND OBJECTIVES: In the 3-year Tolvaptan Efficacy and Safety in Management of ADPKD and Its Outcomes (TEMPO) 3:4 and 1-year Replicating Evidence of Preserved Renal Function: an Investigation of Tolvaptan Safety and Efficacy in ADPKD (REPRISE) trials, tolvaptan slowed the decline of eGFR in patients with autosomal dominant polycystic kidney disease at early and later stages of CKD, respectively. Our objective was to ascertain whether the reduction associated with the administration of tolvaptan is sustained, cumulative, and likely to delay the need for kidney replacement therapy...
August 7, 2018: Clinical Journal of the American Society of Nephrology: CJASN
https://read.qxmd.com/read/29998996/clinical-effect-of-long-term-administration-of-tolvaptan-in-patients-with-heart-failure-and-chronic-kidney-disease
#15
Yohei Ono, Hiroto Takamatsu, Masahiro Inoue, Yukio Mabuchi, Tetsuya Ueda, Tadashi Suzuki, Masahiko Kurabayashi
The effectiveness of long-term administration of tolvaptan in heart failure (HF) patients with chronic kidney disease (CKD) has not been fully studied. Hence, in this study, we investigated the effects of chronic administration of tolvaptan on patients with HF and CKD. We consecutively enrolled 31 patients with acute HF syndrome (AHFS) who were administrated tolvaptan as a long-term medication (TLV group). All patients had a history of prior HF admission and CKD. We also consecutively enrolled 27 patients with AHFS, a prior history of HF and CKD (conventional group)...
2018: Drug Discoveries & Therapeutics
https://read.qxmd.com/read/29934667/comparison-of-the-effects-of-tolvaptan-and-furosemide-on-renal-water-and-sodium-excretion-in-patients-with-heart-failure-and-advanced-chronic-kidney-disease-a-subanalysis-of-the-k-star-study
#16
Naoto Tominaga, Keisuke Kida, Takayuki Inomata, Naoki Sato, Tohru Izumi, Yoshihiro J Akashi, Yugo Shibagaki
BACKGROUND: Tolvaptan (TLV) is known to increase electrolyte-free water clearance. However, TLV actions on renal electrolytes including urine sodium (uNa) excretion and its consequences are less well understood. This subanalysis investigated the effect of add-on TLV compared to increased furosemide (FUR) on both electrolyte-free water and electrolyte clearance in patients with congestive heart failure (CHF) complicated by advanced chronic kidney disease (CKD). METHODS: The Kanagawa Aquaresis Investigators Trial of TLV on HF Patients with Renal Impairment (K-STAR) was a multicenter, open-labeled, randomized, and controlled prospective clinical study...
June 22, 2018: Clinical and Experimental Nephrology
https://read.qxmd.com/read/26239456/hyponatremia-associated-with-heart-failure-pathological-role-of-vasopressin-dependent-impaired-water-excretion
#17
REVIEW
San-E Ishikawa
An exaggerated increase in circulatory blood volume is linked to congestive heart failure. Despite this increase, reduction of the "effective circulatory blood volume" in congestive heart failure is associated with decreased cardiac output, and can weaken the sensitivity of baroreceptors. Thereafter, tonic inhibition of the baroreceptor-mediated afferent pathway of vagal nerves is removed, providing an increase in non-osmotic release of arginine vasopressin (AVP). In the renal collecting duct, the aquaporin-2 (AQP2) water channel is regulated by sustained elevation of AVP release, and this leads to augmented hydroosmotic action of AVP, that results in exaggerated water retention and dilutional hyponatremia...
2015: Journal of Clinical Medicine
https://read.qxmd.com/read/29801549/tolvaptan-for-the-syndrome-of-inappropriate-secretion-of-antidiuretic-hormone-is-the-dose-too-high
#18
EDITORIAL
Richard H Sterns
No abstract text is available yet for this article.
June 2018: American Journal of Kidney Diseases: the Official Journal of the National Kidney Foundation
https://read.qxmd.com/read/29655243/tolvaptan-alleviates-excessive-fluid-retention-of-nephrotic-diabetic-renal-failure-unresponsive-to-furosemide
#19
Tesshu Takada, Tsuguto Masaki, Ayako Hoshiyama, Takuya Toki, Yuji Kamata, Masayoshi Shichiri
Patients with diabetic nephropathy develop nephrotic syndrome, and may show limited response to conventional therapy. They often require earlier initiation of renal replacement therapy because they become refractory to diuretics, and experience excessive fluid retention. We aimed to investigate the efficacy of tolvaptan, an oral arginine vasopressin type 2 receptor antagonist, in a case series of 14 severe diabetic renal failure patients who were severely refractory to maximal doses of furosemide and had excessive fluid retention despite preserved cardiac function and residual renal function...
April 14, 2018: Nephrology
https://read.qxmd.com/read/29154417/impact-of-chronic-kidney-disease-on-the-diuretic-response-of-tolvaptan-in-acute-decompensated-heart-failure
#20
Shuntaro Ikeda, Kiyotaka Ohshima, Shigehiro Miyazaki, Hisaki Kadota, Hideaki Shimizu, Akiyoshi Ogimoto, Mareomi Hamada
AIM: This study investigated the relationship between the initial diuretic response to tolvaptan and clinical predictors for tolvaptan responders in patients with acute decompensated heart failure (ADHF). METHODS AND RESULTS: Patients (153) with ADHF (clinical scenario 2 or 3 with signs of fluid retention) who were administered tolvaptan were enrolled. Tolvaptan (15 or 7.5 mg) was administered for at least 7 days to those patients in whom fluid retention was observed even after standard treatment...
November 2017: ESC Heart Failure
label_collection
label_collection
1617
1
2
2018-04-11 21:33:57
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"